Brink Biologics
brinkbiologics.com
Health Care
Biologics & Biosimilars
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Brink Biologics Announces License Agreement with Global Healthcare Company Fresenius Kabi SwissBioSim GmbH
SAN DIEGO, Calif., September 10, 2020 - Brink Biologics, Inc. ("Brink"), a NantKwest, Inc. (NASDAQ: NK) affiliate and exclusively-licensed distributor of NantKwest's proprietary off-the-shelf NK-92 natural killer cells in certain fields, announces the lic
Read more
Report
Brink Biologics Announces License Agreement with Global Healthcare Company Fresenius Kabi SwissBioSim GmbH
Brink Biologics, Inc., a NantKwest, Inc. affiliate and exclusively-licensed distributor of NantKwest' s proprietary off-the-shelf NK-92 natural killer cells in certain fields, announces the licensing of its next-generation natural killer-based bioanalytic
Read more
Report
Brink Biologics Announces License Agreement with Global Healthcare Company Fresenius Kabi SwissBioSim GmbH
Read more
Report
Brink Biologics Announces Research License Agreement with Worcester Polytechnic Institute for Use of NantKwest's NK-92 Cells
NK-92 Cell Based Bioanalytical Solutions are the Key to Optimizing R&D and Commercial Product Development Efforts for Monoclonal Antibodies, Bi-Specifics and Related Biological Products SAN DIEGO-May 1, 2019- Brink Biologics, Inc., a NantKwest, Inc. (Nasd
Read more
Report
Brink Biologics Announces Research License Agreement with Worcester Polytechnic Institute for Use of NantKwest's NK-92 Cells
Read more
Report
NantKwest Announces New haNK Natural Killer Cell Patent Issuance Further Expanding Intellectual Property Estate
New haNK and T-haNK Based Natural Killer Cell Therapy Programs to Transition to Human Clinical Trials in 2019 CULVER CITY, CA - April 1, 2019 - NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announce
Read more
Report